ACE and type 2 diabetes mellitus: The study developed a PERGENE risk model to guide individualized therapy with perindopril and concluded that personalized ACE-inhibitor therapy using clinical and pharmacogenetic factors significantly enhances treatment benefits and cost-effectiveness in stable CAD patients.[32] The CoRDia study investigated a 19-SNP coronary heart disease (CHD) gene score profile in individuals with type 2 diabetes.